Prevalence of Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Dataset

被引:13
|
作者
Lieber, Sarah B. [1 ,2 ]
Navarro-Millan, Iris [1 ,2 ]
Rajan, Mangala [2 ]
Curtis, Jeffrey R. [3 ]
Sattui, Sebastian E. [4 ]
Lui, Geyanne [5 ]
Schwartzman, Sergio [1 ,2 ]
Mandl, Lisa A. [1 ,2 ]
机构
[1] Hosp Special Surg, New York, NY USA
[2] Weill Cornell Med, New York, NY USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] New York Inst Technol, Coll Osteopath Med, Old Westbury, NY 11568 USA
基金
美国国家卫生研究院;
关键词
WOMENS HEALTH; VALIDATION; ADULTS; INDEX;
D O I
10.1002/acr2.11388
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Frailty is associated with disability and mortality independent of age. Although studies have evaluated frailty in rheumatoid arthritis (RA), information on the prevalence of frailty in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) is limited. We aimed to determine the prevalence of frailty in AS and PsA and to evaluate whether characteristics known to be associated with frailty, including anxiety, differ among these three types of inflammatory arthritis. Methods We performed a cross sectional study of Centers for Medicare & Medicaid Services (CMS) beneficiaries aged 65 years or older with AS, PsA, or RA enrolled in 2014. We operationalized frailty using a validated claims-based frailty index. We also explored the prevalence of frailty among CMS beneficiaries younger than age 65 years with work disability, a younger population that also may be at risk of frailty. Results The prevalence of frailty in beneficiaries aged 65 years or older with AS and PsA was 45.2% and 46.7%, respectively, significantly lower than in RA (65.9%, P < 0.05). The prevalence of frailty in beneficiaries less than 65 years old was much lower overall, though still highest in RA; 11.7%, 4.4%, and 7.0% in RA, AS, and PsA, respectively (P < 0.05). Anxiety was significantly associated with frailty in subjects of all ages, particularly among those less than 65 years old (P < 0.05). Conclusion Almost half of beneficiaries with AS or PsA aged 65 years old or older were frail, higher than in younger disabled beneficiaries. Further studies are needed to understand the risks of developing frailty in these diseases. Frailty was associated with anxiety, particularly in the younger age groups.
引用
收藏
页码:300 / 305
页数:6
相关论文
共 50 条
  • [41] Duration Of Symptoms Before Diagnosis In Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis.
    Hetland, Merete Lund
    Sorensen, Jan
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S42 - S43
  • [42] Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
    Leu, Jocelyn H.
    Adedokun, Omoniyi J.
    Gargano, Cynthia
    Hsia, Elizabeth C.
    Xu, Zhenhua
    Shankar, Gopi
    RHEUMATOLOGY, 2019, 58 (03) : 441 - 446
  • [43] Comparison of the annual direct and indirect costs in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
    Huscher, D
    Thiele, K
    Merkesdal, S
    Zeidler, H
    Zink, A
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S93 - S93
  • [44] Weight Change before and after Diagnosis in Patients with Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis
    Ogdie, Alexis
    George, Michael D.
    Gelfand, Joel
    Dubreuil, Maureen
    Love, Thorvardur
    Baker, Joshua
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [45] GOLIMUMAB UTILIZATION PATTERNS AND REFILL ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Ellis, L.
    Bolge, S.
    Rice, P.
    VALUE IN HEALTH, 2014, 17 (03) : A49 - A50
  • [46] Golimumab: a new anti-TNF-α agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
    Voulgari, Paraskevi V.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (05) : 721 - 733
  • [47] Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany
    Huscher, D.
    Merkesdal, S.
    Thiele, K.
    Zeidler, H.
    Schneider, M.
    Zink, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (09) : 1175 - 1183
  • [48] PATIENT ELIGIBILITY AND USE OF BIOLOGICS IN RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS IN THE UNITED STATES
    Narayanan, S.
    Baskett, A.
    Lu, Y.
    Hutchings, R.
    VALUE IN HEALTH, 2013, 16 (07) : A572 - A572
  • [49] Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
    Cantini, Fabrizio
    Niccoli, Laura
    Nannini, Carlotta
    Cassara, Emanuele
    Kaloudi, Olga
    Favalli, Ennio Giulio
    Becciolini, Andrea
    Benucci, Maurizio
    Gobbi, Francesca Li
    Guiducci, Serena
    Foti, Rosario
    Mosca, Marta
    Goletti, Delia
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 47 (02) : 183 - 192
  • [50] THE EFFECT OF PREGNANCY ON ANKYLOSING-SPONDYLITIS, PSORIATIC-ARTHRITIS, AND JUVENILE RHEUMATOID-ARTHRITIS
    OSTENSEN, M
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1992, 28 (3-4) : 235 - 237